IP Library Granted Patent US 9,376,665
Granted Patent B2
US 9,376,665 · App. 13/882,904 · Granted Jun 28, 2016

Method for producing intestinal cells

Inventors: Shoen Kume (Kumamoto, JP); Soichiro Ogaki (Fukuoka, JP); Nobuaki Shiraki (Kumamoto, JP); Kazuhiko Kume (Kumamoto, JP)
Assignees: National University Corporation Kumamoto University; LSIP, LLC
C12N5/0679C12Q1/6881G01N33/5064G01N33/5073C12N2501/115C12N2501/117C12N2501/119C12N2501/16C12N2501/415C12N2501/42C12N2501/999C12N2502/13C12N2506/02C12Q2600/158G01N2500/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,376,665
App. No.
13/882,904
Granted
Jun 28, 2016
Kind
B2
Abstract

An object of the present invention is to provide a method of producing intestinal cells by use of pluripotent stem cells as a starting material. According to the present invention, provided is a method of producing intestinal cells, comprising the steps of: (A) inducing differentiation of pluripotent stem cells into definitive endoderm cells; and (B) culturing the definitive endoderm cells in the presence of (2′Z,3′E)-6-bromoindirubin-3′-oxime (BIO) and N-[(3,5-difluorophenyl)acetyl]-L-Ala-2-phenyl-L-Gly-tert-butyl-OH (DAPT) to thereby induce differentiation of the definitive endoderm cells into intestinal cells.

Claims (7)

1. A method of producing intestinal cells expressing Cdx2, comprising the steps of:

(a) obtaining mouse or human embryonic stem (ES) cells,

(b) culturing the ES cells of step (a) with Activin and/or bFGF to produce definitive endoderm cells,

(c) culturing the definitive endoderm cells of step (b) with (2′Z,3′E)-6-bromoindirubin-3′-oxime (BIO) and N-[(3,5-difluorophenyl)acetyl]-L-Ala-2-phenyl-L-Gly-tert-butyl-OH (DAPT) and in the presence of M15 cells or MEF cells, to thereby induce differentiation of the definitive endoderm cells into intestinal cells expressing Cdx2.

2. The method according to claim 1 , wherein the definitive endoderm cells are separated from a cell culture obtained in step (b) by flow cytometry using fluorescently-labelled antibodies against E-cadherin (ECD) and CXCR4, and said separated definitive endoderm cells are used in the step (c).

3. The method according to claim 1 , wherein the ES cells are cultured in the presence of feeder cells.

4. The method according to claim 3 , wherein the feeder cells are cells derived from a mesoderm.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2017
From: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY; LSIP, LLC
To: TOKYO INSTITUTE OF TECHNOLOGY
Reel/Frame 041099/0678 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2013
From: KUME, SHOEN; OGAKI, SOICHIRO; SHIRAKI, NOBUAKI; KUME, KAZUHIKO
To: NATIONAL UNIVERSITY CORP. KUMAMOTO UNIVERSITY; LSIP, LLC
Reel/Frame 030749/0715 →
Priority Claims (1)
JP 2010-246161 · Nov 2, 2010 · national
Continuity (1)
Related Publication 20140199700A1 · Jul 17, 2014